25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CSBTF (Kuros Biosciences AG) Stock Analysis
Buy, Hold or Sell?

Let's analyze Kuros Biosciences AG together

I guess you are interested in Kuros Biosciences AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Kuros Biosciences AG’s Financial Insights
  • 📈 Technical Analysis (TA) – Kuros Biosciences AG’s Price Targets

I'm going to help you getting a better view of Kuros Biosciences AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Kuros Biosciences AG

I send you an email if I find something interesting about Kuros Biosciences AG.

1. Quick Overview

1.1. Quick analysis of Kuros Biosciences AG (30 sec.)










1.2. What can you expect buying and holding a share of Kuros Biosciences AG? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.92
Expected worth in 1 year
$2.19
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
$0.27
Return On Investment
0.7%

For what price can you sell your share?

Current Price per Share
$35.55
Expected price per share
$33.22 - $36.10
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Kuros Biosciences AG (5 min.)




Live pricePrice per Share (EOD)
$35.55
Intrinsic Value Per Share
$1.23 - $2.46
Total Value Per Share
$3.16 - $4.38

2.2. Growth of Kuros Biosciences AG (5 min.)




Is Kuros Biosciences AG growing?

Current yearPrevious yearGrowGrow %
How rich?$73.7m$71.2m$2.5m3.5%

How much money is Kuros Biosciences AG making?

Current yearPrevious yearGrowGrow %
Making money-$3.7m-$13.7m$10m269.4%
Net Profit Margin-4.9%-40.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Kuros Biosciences AG (5 min.)




2.4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Kuros Biosciences AG?

Welcome investor! Kuros Biosciences AG's management wants to use your money to grow the business. In return you get a share of Kuros Biosciences AG.

First you should know what it really means to hold a share of Kuros Biosciences AG. And how you can make/lose money.

Speculation

The Price per Share of Kuros Biosciences AG is $35.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kuros Biosciences AG.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kuros Biosciences AG, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.92. Based on the TTM, the Book Value Change Per Share is $0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kuros Biosciences AG.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-0.3%-0.10-0.3%-0.36-1.0%-0.28-0.8%-0.27-0.7%-0.30-0.9%
Usd Book Value Change Per Share0.070.2%0.070.2%-0.40-1.1%-0.20-0.6%-0.13-0.4%0.280.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.070.2%0.070.2%-0.40-1.1%-0.20-0.6%-0.13-0.4%0.280.8%
Usd Price Per Share22.57-22.57-3.85-9.45-6.66-3.33-
Price to Earnings Ratio-233.13--233.13--10.77--82.98--53.98--26.99-
Price-to-Total Gains Ratio338.75-338.75--9.69-107.28-64.50-64.50-
Price to Book Ratio11.74-11.74-2.07-4.89-3.31-1.65-
Price-to-Total Gains Ratio338.75-338.75--9.69-107.28-64.50-64.50-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share35.5505
Number of shares28
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.07-0.13
Usd Total Gains Per Share0.07-0.13
Gains per Quarter (28 shares)1.87-3.50
Gains per Year (28 shares)7.46-14.01
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
107-30-14-24
201540-28-38
3022110-42-52
4030180-56-66
5037250-70-80
6045320-84-94
7052390-98-108
8060460-112-122
9067530-126-136
10075600-140-150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.021.00.00.0%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%7.03.00.070.0%10.011.00.047.6%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.021.00.0%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%7.03.00.070.0%10.011.00.047.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Kuros Biosciences AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0670.0670%-0.398+697%-0.199+398%-0.125+288%0.278-76%
Book Value Per Share--1.9231.9230%1.856+4%2.011-4%2.264-15%2.004-4%
Current Ratio--2.1412.1410%2.062+4%2.232-4%3.675-42%3.946-46%
Debt To Asset Ratio--0.3050.3050%0.206+48%0.227+34%0.188+62%0.223+37%
Debt To Equity Ratio--0.4390.4390%0.260+69%0.301+46%0.241+82%0.565-22%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--855852282.000855852282.0000%147112348.350+482%363065190.750+136%264100902.810+224%264100902.810+224%
Eps---0.097-0.0970%-0.358+269%-0.278+187%-0.266+175%-0.302+212%
Ev To Ebitda Ratio---1525.583-1525.5830%-14.133-99%-516.490-66%-316.965-79%-316.965-79%
Ev To Sales Ratio--11.32811.3280%4.383+158%6.835+66%11.497-1%11.497-1%
Free Cash Flow Per Share--0.0660.0660%-0.300+552%-0.162+345%-0.198+398%-0.256+486%
Free Cash Flow To Equity Per Share--0.1100.1100%-0.306+378%-0.115+204%-0.017+116%-0.051+146%
Gross Profit Margin--10.73610.7360%2.248+378%4.846+122%3.462+210%2.254+376%
Intrinsic Value_10Y_max--2.457----------
Intrinsic Value_10Y_min--1.234----------
Intrinsic Value_1Y_max---0.075----------
Intrinsic Value_1Y_min---0.162----------
Intrinsic Value_3Y_max--0.021----------
Intrinsic Value_3Y_min---0.243----------
Intrinsic Value_5Y_max--0.410----------
Intrinsic Value_5Y_min---0.054----------
Market Cap1364552616.750+37%866315595.000866315595.0000%147795666.750+486%362602527.250+139%255561181.350+239%127780590.675+578%
Net Profit Margin---0.049-0.0490%-0.409+732%-0.423+760%-0.934+1798%-7.391+14928%
Operating Margin---0.042-0.0420%-0.392+827%-0.361+754%-0.892+2008%-7.976+18750%
Operating Ratio--1.0661.0660%1.393-23%1.402-24%1.947-45%8.842-88%
Pb Ratio18.492+37%11.74011.7400%2.075+466%4.889+140%3.309+255%1.655+610%
Pe Ratio-367.210-58%-233.131-233.1310%-10.767-95%-82.982-64%-53.985-77%-26.992-88%
Price Per Share35.551+37%22.57022.5700%3.851+486%9.447+139%6.658+239%3.329+578%
Price To Free Cash Flow Ratio535.671+37%340.082340.0820%-12.831+104%106.560+219%59.711+470%29.855+1039%
Price To Total Gains Ratio533.566+37%338.746338.7460%-9.686+103%107.277+216%64.497+425%64.497+425%
Quick Ratio--1.5501.5500%1.590-2%1.758-12%3.110-50%3.484-56%
Return On Assets---0.035-0.0350%-0.153+337%-0.109+212%-0.098+181%0.031-214%
Return On Equity---0.050-0.0500%-0.193+283%-0.137+173%-0.120+138%0.599-108%
Total Gains Per Share--0.0670.0670%-0.398+697%-0.199+398%-0.125+288%0.278-76%
Usd Book Value--73793362.80073793362.8000%71235943.200+4%77174784.000-4%86896244.340-15%76919293.260-4%
Usd Book Value Change Per Share--0.0670.0670%-0.398+697%-0.199+398%-0.125+288%0.278-76%
Usd Book Value Per Share--1.9231.9230%1.856+4%2.011-4%2.264-15%2.004-4%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--855852282.000855852282.0000%147112348.350+482%363065190.750+136%264100902.810+224%264100902.810+224%
Usd Eps---0.097-0.0970%-0.358+269%-0.278+187%-0.266+175%-0.302+212%
Usd Free Cash Flow--2547370.8002547370.8000%-11518437.000+552%-6234443.000+345%-7580814.720+398%-9841669.110+486%
Usd Free Cash Flow Per Share--0.0660.0660%-0.300+552%-0.162+345%-0.198+398%-0.256+486%
Usd Free Cash Flow To Equity Per Share--0.1100.1100%-0.306+378%-0.115+204%-0.017+116%-0.051+146%
Usd Market Cap1364552616.750+37%866315595.000866315595.0000%147795666.750+486%362602527.250+139%255561181.350+239%127780590.675+578%
Usd Price Per Share35.551+37%22.57022.5700%3.851+486%9.447+139%6.658+239%3.329+578%
Usd Profit---3716000.000-3716000.0000%-13727000.000+269%-10679333.333+187%-10219800.000+175%-10404500.000+180%
Usd Revenue--75555000.00075555000.0000%33564000.000+125%42368333.333+78%28991800.000+161%15618500.000+384%
Usd Total Gains Per Share--0.0670.0670%-0.398+697%-0.199+398%-0.125+288%0.278-76%
 EOD+5 -3MRQTTM+0 -0YOY+31 -73Y+27 -115Y+26 -1210Y+21 -17

3.3 Fundamental Score

Let's check the fundamental score of Kuros Biosciences AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-367.210
Price to Book Ratio (EOD)Between0-118.492
Net Profit Margin (MRQ)Greater than0-0.049
Operating Margin (MRQ)Greater than0-0.042
Quick Ratio (MRQ)Greater than11.550
Current Ratio (MRQ)Greater than12.141
Debt to Asset Ratio (MRQ)Less than10.305
Debt to Equity Ratio (MRQ)Less than10.439
Return on Equity (MRQ)Greater than0.15-0.050
Return on Assets (MRQ)Greater than0.05-0.035
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Kuros Biosciences AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose35.551
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Kuros Biosciences AG

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Fundamental data was last updated by Penke on 2025-06-28 20:48:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Kuros Biosciences AG earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Kuros Biosciences AG to the Medical Devices industry mean.
  • A Net Profit Margin of -4.9% means that $-0.05 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kuros Biosciences AG:

  • The MRQ is -4.9%. The company is making a loss. -1
  • The TTM is -4.9%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-4.9%TTM-4.9%0.0%
TTM-4.9%YOY-40.9%+36.0%
TTM-4.9%5Y-93.4%+88.4%
5Y-93.4%10Y-739.1%+645.8%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.9%-7.9%+3.0%
TTM-4.9%-10.4%+5.5%
YOY-40.9%-13.5%-27.4%
3Y-42.3%-14.5%-27.8%
5Y-93.4%-10.7%-82.7%
10Y-739.1%-11.1%-728.0%
4.3.1.2. Return on Assets

Shows how efficient Kuros Biosciences AG is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kuros Biosciences AG to the Medical Devices industry mean.
  • -3.5% Return on Assets means that Kuros Biosciences AG generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kuros Biosciences AG:

  • The MRQ is -3.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.5%TTM-3.5%0.0%
TTM-3.5%YOY-15.3%+11.8%
TTM-3.5%5Y-9.8%+6.3%
5Y-9.8%10Y3.1%-12.9%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.5%-2.1%-1.4%
TTM-3.5%-2.4%-1.1%
YOY-15.3%-3.5%-11.8%
3Y-10.9%-2.9%-8.0%
5Y-9.8%-2.7%-7.1%
10Y3.1%-2.4%+5.5%
4.3.1.3. Return on Equity

Shows how efficient Kuros Biosciences AG is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kuros Biosciences AG to the Medical Devices industry mean.
  • -5.0% Return on Equity means Kuros Biosciences AG generated $-0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kuros Biosciences AG:

  • The MRQ is -5.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.0%TTM-5.0%0.0%
TTM-5.0%YOY-19.3%+14.2%
TTM-5.0%5Y-12.0%+6.9%
5Y-12.0%10Y59.9%-71.8%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.0%-2.0%-3.0%
TTM-5.0%-3.2%-1.8%
YOY-19.3%-3.9%-15.4%
3Y-13.7%-4.0%-9.7%
5Y-12.0%-4.4%-7.6%
10Y59.9%-6.3%+66.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Kuros Biosciences AG.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Kuros Biosciences AG is operating .

  • Measures how much profit Kuros Biosciences AG makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kuros Biosciences AG to the Medical Devices industry mean.
  • An Operating Margin of -4.2% means the company generated $-0.04  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kuros Biosciences AG:

  • The MRQ is -4.2%. The company is operating very inefficient. -2
  • The TTM is -4.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-4.2%TTM-4.2%0.0%
TTM-4.2%YOY-39.2%+35.0%
TTM-4.2%5Y-89.2%+85.0%
5Y-89.2%10Y-797.6%+708.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.2%-12.1%+7.9%
TTM-4.2%-13.7%+9.5%
YOY-39.2%-11.9%-27.3%
3Y-36.1%-11.3%-24.8%
5Y-89.2%-10.3%-78.9%
10Y-797.6%-12.2%-785.4%
4.3.2.2. Operating Ratio

Measures how efficient Kuros Biosciences AG is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 1.07 means that the operating costs are $1.07 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Kuros Biosciences AG:

  • The MRQ is 1.066. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.066. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.066TTM1.0660.000
TTM1.066YOY1.393-0.327
TTM1.0665Y1.947-0.880
5Y1.94710Y8.842-6.896
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0661.397-0.331
TTM1.0661.389-0.323
YOY1.3931.295+0.098
3Y1.4021.342+0.060
5Y1.9471.375+0.572
10Y8.8421.328+7.514
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Kuros Biosciences AG.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Kuros Biosciences AG is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 2.14 means the company has $2.14 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Kuros Biosciences AG:

  • The MRQ is 2.141. The company is able to pay all its short-term debts. +1
  • The TTM is 2.141. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.141TTM2.1410.000
TTM2.141YOY2.062+0.079
TTM2.1415Y3.675-1.534
5Y3.67510Y3.946-0.271
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1412.473-0.332
TTM2.1412.589-0.448
YOY2.0622.630-0.568
3Y2.2322.884-0.652
5Y3.6753.528+0.147
10Y3.9463.291+0.655
4.4.3.2. Quick Ratio

Measures if Kuros Biosciences AG is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kuros Biosciences AG to the Medical Devices industry mean.
  • A Quick Ratio of 1.55 means the company can pay off $1.55 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kuros Biosciences AG:

  • The MRQ is 1.550. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.550. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.550TTM1.5500.000
TTM1.550YOY1.590-0.040
TTM1.5505Y3.110-1.560
5Y3.11010Y3.484-0.374
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5501.079+0.471
TTM1.5501.398+0.152
YOY1.5901.638-0.048
3Y1.7581.815-0.057
5Y3.1102.139+0.971
10Y3.4842.338+1.146
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Kuros Biosciences AG.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Kuros Biosciences AG assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kuros Biosciences AG to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.31 means that Kuros Biosciences AG assets are financed with 30.5% credit (debt) and the remaining percentage (100% - 30.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kuros Biosciences AG:

  • The MRQ is 0.305. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.305. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.305TTM0.3050.000
TTM0.305YOY0.206+0.099
TTM0.3055Y0.188+0.117
5Y0.18810Y0.223-0.035
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3050.409-0.104
TTM0.3050.419-0.114
YOY0.2060.401-0.195
3Y0.2270.391-0.164
5Y0.1880.424-0.236
10Y0.2230.457-0.234
4.5.4.2. Debt to Equity Ratio

Measures if Kuros Biosciences AG is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kuros Biosciences AG to the Medical Devices industry mean.
  • A Debt to Equity ratio of 43.9% means that company has $0.44 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kuros Biosciences AG:

  • The MRQ is 0.439. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.439. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.439TTM0.4390.000
TTM0.439YOY0.260+0.179
TTM0.4395Y0.241+0.198
5Y0.24110Y0.565-0.324
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4390.608-0.169
TTM0.4390.648-0.209
YOY0.2600.623-0.363
3Y0.3010.644-0.343
5Y0.2410.683-0.442
10Y0.5650.757-0.192
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Kuros Biosciences AG generates.

  • Above 15 is considered overpriced but always compare Kuros Biosciences AG to the Medical Devices industry mean.
  • A PE ratio of -233.13 means the investor is paying $-233.13 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kuros Biosciences AG:

  • The EOD is -367.210. Based on the earnings, the company is expensive. -2
  • The MRQ is -233.131. Based on the earnings, the company is expensive. -2
  • The TTM is -233.131. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-367.210MRQ-233.131-134.079
MRQ-233.131TTM-233.1310.000
TTM-233.131YOY-10.767-222.364
TTM-233.1315Y-53.985-179.147
5Y-53.98510Y-26.992-26.992
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-367.210-1.295-365.915
MRQ-233.131-1.518-231.613
TTM-233.131-1.257-231.874
YOY-10.767-2.406-8.361
3Y-82.982-1.572-81.410
5Y-53.985-1.938-52.047
10Y-26.992-1.705-25.287
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kuros Biosciences AG:

  • The EOD is 535.671. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 340.082. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 340.082. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD535.671MRQ340.082+195.589
MRQ340.082TTM340.0820.000
TTM340.082YOY-12.831+352.913
TTM340.0825Y59.711+280.372
5Y59.71110Y29.855+29.855
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD535.671-2.842+538.513
MRQ340.082-3.183+343.265
TTM340.082-1.612+341.694
YOY-12.831-3.401-9.430
3Y106.560-2.458+109.018
5Y59.711-3.239+62.950
10Y29.855-3.398+33.253
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Kuros Biosciences AG is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 11.74 means the investor is paying $11.74 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Kuros Biosciences AG:

  • The EOD is 18.492. Based on the equity, the company is expensive. -2
  • The MRQ is 11.740. Based on the equity, the company is expensive. -2
  • The TTM is 11.740. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD18.492MRQ11.740+6.752
MRQ11.740TTM11.7400.000
TTM11.740YOY2.075+9.665
TTM11.7405Y3.309+8.431
5Y3.30910Y1.655+1.655
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD18.4922.030+16.462
MRQ11.7401.966+9.774
TTM11.7402.162+9.578
YOY2.0752.656-0.581
3Y4.8892.683+2.206
5Y3.3093.822-0.513
10Y1.6554.189-2.534
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-12-312021-12-312022-12-312023-12-312024-12-31
Total Other Income Expense Net -415-372-787-1,758-2,5452,390-1551,8041,649



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in CHF. All numbers in thousands.

Summary
Total Assets84,538
Total Liabilities25,790
Total Stockholder Equity58,748
 As reported
Total Liabilities 25,790
Total Stockholder Equity+ 58,748
Total Assets = 84,538

Assets

Total Assets84,538
Total Current Assets44,754
Long-term Assets39,784
Total Current Assets
Cash And Cash Equivalents 17,460
Net Receivables 14,932
Inventory 9,443
Other Current Assets 2,919
Total Current Assets  (as reported)44,754
Total Current Assets  (calculated)44,754
+/-0
Long-term Assets
Property Plant Equipment 3,024
Goodwill 19,433
Intangible Assets 14,991
Long-term Assets  (as reported)39,784
Long-term Assets  (calculated)37,448
+/- 2,336

Liabilities & Shareholders' Equity

Total Current Liabilities20,899
Long-term Liabilities4,891
Total Stockholder Equity58,748
Total Current Liabilities
Short-term Debt 529
Accounts payable 6,912
Other Current Liabilities 13,458
Total Current Liabilities  (as reported)20,899
Total Current Liabilities  (calculated)20,899
+/-0
Long-term Liabilities
Capital Lease Obligations 1,793
Long-term Liabilities  (as reported)4,891
Long-term Liabilities  (calculated)1,793
+/- 3,098
Total Stockholder Equity
Common Stock3,787
Retained Earnings -45,427
Other Stockholders Equity 100,388
Total Stockholder Equity (as reported)58,748
Total Stockholder Equity (calculated)58,748
+/-0
Other
Capital Stock3,787
Cash and Short Term Investments 17,460
Common Stock Shares Outstanding 37,199
Liabilities and Stockholders Equity 84,538
Net Debt -15,667
Net Invested Capital 58,748
Net Working Capital 23,855
Property Plant and Equipment Gross 4,395
Short Long Term Debt Total 1,793



6.3. Balance Sheets Structured

Currency in CHF. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-31
> Total Assets 
88,366
82,394
57,412
123,559
110,755
68,702
54,071
30,813
30,391
40,502
17,631
3,259
43,768
86,081
85,821
87,852
94,364
91,336
82,946
71,464
84,538
84,53871,46482,94691,33694,36487,85285,82186,08143,7683,25917,63140,50230,39130,81354,07168,702110,755123,55957,41282,39488,366
   > Total Current Assets 
67,279
63,746
44,496
112,625
99,637
62,661
50,048
30,570
30,237
40,337
17,551
3,179
13,396
17,674
19,833
23,290
33,968
32,892
31,393
27,194
44,754
44,75427,19431,39332,89233,96823,29019,83317,67413,3963,17917,55140,33730,23730,57050,04862,66199,637112,62544,49663,74667,279
       Cash And Cash Equivalents 
21,033
11,469
9,149
43,043
40,322
20,969
33,782
24,542
28,585
39,847
16,935
2,093
12,369
16,673
18,334
20,802
28,388
28,623
24,065
14,208
17,460
17,46014,20824,06528,62328,38820,80218,33416,67312,3692,09316,93539,84728,58524,54233,78220,96940,32243,0439,14911,46921,033
       Short-term Investments 
0
379
18,000
66,000
41,000
37,000
8,000
4,000
0
0
0
65
0
0
0
0
0
0
0
342
0
03420000000650004,0008,00037,00041,00066,00018,0003790
       Net Receivables 
1,053
845
0
0
0
0
0
0
0
0
0
14
308
154
214
759
1,036
1,691
2,817
6,411
14,932
14,9326,4112,8171,6911,036759214154308140000000008451,053
       Inventory 
14,124
14,124
14,124
0
0
0
0
0
0
0
0
0
276
220
547
954
1,460
1,757
3,170
4,856
9,443
9,4434,8563,1701,7571,46095454722027600000000014,12414,12414,124
       Other Current Assets 
31,069
36,929
3,223
3,582
18,315
4,692
8,266
2,028
1,652
490
616
217
719
627
738
775
3,084
821
1,341
1,719
2,919
2,9191,7191,3418213,0847757386277192176164901,6522,0288,2664,69218,3153,5823,22336,92931,069
   > Long-term Assets 
21,087
18,648
12,916
10,934
11,118
6,041
4,023
243
154
165
80
80
30,372
68,407
65,988
64,562
60,396
58,444
51,553
44,270
39,784
39,78444,27051,55358,44460,39664,56265,98868,40730,37280801651542434,0236,04111,11810,93412,91618,64821,087
       Property Plant Equipment 
14,037
13,591
12,575
10,643
8,383
5,993
3,968
137
86
93
0
3
45
630
634
2,782
2,588
2,447
2,323
2,642
3,024
3,0242,6422,3232,4472,5882,782634630453093861373,9685,9938,38310,64312,57513,59114,037
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
23,717
34,546
34,241
33,860
33,847
33,390
29,314
24,469
19,433
19,43324,46929,31433,39033,84733,86034,24134,54623,717000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
6,595
33,231
31,113
27,920
23,666
22,607
19,412
16,508
14,991
14,99116,50819,41222,60723,66627,92031,11333,2316,595000000000000
       Long-term Assets Other 
7,050
404
18,310
66,254
43,500
37,000
8,000
4,045
68
72
0
62
15
38
-1,818
-64,562
-60,101
-58,444
-51,049
651
0
0651-51,049-58,444-60,101-64,562-1,818381562072684,0458,00037,00043,50066,25418,3104047,050
> Total Liabilities 
8,191
8,383
11,512
69,125
78,895
60,461
47,476
42,493
20,362
36,272
43,851
2,590
5,446
12,941
9,338
9,997
9,763
14,360
14,086
14,752
25,790
25,79014,75214,08614,3609,7639,9979,33812,9415,4462,59043,85136,27220,36242,49347,47660,46178,89569,12511,5128,3838,191
   > Total Current Liabilities 
4,647
5,253
8,551
8,014
14,333
4,859
4,469
39,560
3,490
5,810
43,851
1,696
3,265
4,656
4,040
3,640
3,876
11,288
12,589
13,187
20,899
20,89913,18712,58911,2883,8763,6404,0404,6563,2651,69643,8515,8103,49039,5604,4694,85914,3338,0148,5515,2534,647
       Short-term Debt 
0
0
132
0
0
0
0
35,715
0
0
37,592
3,695
0
0
0
246
278
317
416
578
529
5295784163172782460003,69537,5920035,715000013200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
3,695
0
0
0
0
0
0
0
0
0
0000000003,69500000000000
       Accounts payable 
1,331
1,264
3,008
1,159
800
253
541
328
362
1,492
152
648
1,273
1,320
1,611
1,059
936
846
1,302
1,301
6,912
6,9121,3011,3028469361,0591,6111,3201,2736481521,4923623285412538001,1593,0081,2641,331
       Other Current Liabilities 
3,316
3,989
5,411
6,855
13,533
4,606
3,928
39
3,128
4,318
6,107
-2,647
1,992
3,336
2,429
2,335
2,662
10,125
10,871
11,308
13,458
13,45811,30810,87110,1252,6622,3352,4293,3361,992-2,6476,1074,3183,128393,9284,60613,5336,8555,4113,9893,316
   > Long-term Liabilities 
3,544
3,130
2,961
61,111
64,562
55,602
43,007
2,933
16,872
30,462
0
894
2,181
8,285
5,298
6,357
5,887
3,072
1,497
1,565
4,891
4,8911,5651,4973,0725,8876,3575,2988,2852,181894030,46216,8722,93343,00755,60264,56261,1112,9613,1303,544
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
606
2,181
8,285
5,298
4,215
3,825
1,243
0
0
0
0001,2433,8254,2155,2988,2852,18160600000000000
> Total Stockholder Equity
80,175
74,011
45,900
54,434
31,860
8,241
6,595
-11,680
10,029
4,230
-26,220
669
38,322
73,140
76,483
77,855
84,601
76,976
68,860
56,712
58,748
58,74856,71268,86076,97684,60177,85576,48373,14038,322669-26,2204,23010,029-11,6806,5958,24131,86054,43445,90074,01180,175
   Common Stock
462
509
517
526
527
527
527
527
2,241
3,053
3,053
3,240
5,084
8,171
15,059
22,470
32,811
3,281
3,656
3,678
3,787
3,7873,6783,6563,28132,81122,47015,0598,1715,0843,2403,0533,0532,241527527527527526517509462
   Retained Earnings -45,427-42,499-116,253-101,166-93,152-81,904-69,433-57,157-43,338-299,990-305,255-270,867-239,542-230,326-211,543-210,079-185,090-159,264-152,391-117,842-89,364
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
169,077
191,344
197,774
213,172
216,423
217,793
217,611
218,673
247,330
272,044
275,982
-277,510
60,642
104,153
112,209
118,143
125,044
154,574
160,140
95,533
100,388
100,38895,533160,140154,574125,044118,143112,209104,15360,642-277,510275,982272,044247,330218,673217,611217,793216,423213,172197,774191,344169,077



6.4. Balance Sheets

Currency in CHF. All numbers in thousands.




6.5. Cash Flows

Currency in CHF. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in CHF. All numbers in thousands.

Gross Profit (+$)
totalRevenue75,555
Cost of Revenue-13,524
Gross Profit62,03162,031
 
Operating Income (+$)
Gross Profit62,031
Operating Expense-67,026
Operating Income-4,995-4,995
 
Operating Expense (+$)
Research Development6,984
Selling General Administrative5,077
Selling And Marketing Expenses36,180
Operating Expense67,02648,241
 
Net Interest Income (+$)
Interest Income163
Interest Expense-149
Other Finance Cost-460
Net Interest Income474
 
Pretax Income (+$)
Operating Income-4,995
Net Interest Income474
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-3,346-6,644
EBIT - interestExpense = -3,346
-3,346
-3,567
Interest Expense149
Earnings Before Interest and Taxes (EBIT)-3,197-3,197
Earnings Before Interest and Taxes (EBITDA)-561
 
After tax Income (+$)
Income Before Tax-3,346
Tax Provision-370
Net Income From Continuing Ops-3,716-3,716
Net Income-3,716
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses80,550
Total Other Income/Expenses Net1,649-474
 

Technical Analysis of Kuros Biosciences AG
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kuros Biosciences AG. The general trend of Kuros Biosciences AG is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kuros Biosciences AG's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Kuros Biosciences AG Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kuros Biosciences AG.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 36.10.

The bearish price targets are: 35.19 > 34.00 > 33.22.

Know someone who trades $CSBTF? Share this with them.👇

Kuros Biosciences AG Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kuros Biosciences AG. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kuros Biosciences AG Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kuros Biosciences AG.

Kuros Biosciences AG Daily Moving Average Convergence/Divergence (MACD) ChartKuros Biosciences AG Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kuros Biosciences AG. The current adx is .

Kuros Biosciences AG Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kuros Biosciences AG.

Kuros Biosciences AG Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kuros Biosciences AG.

Kuros Biosciences AG Daily Relative Strength Index (RSI) ChartKuros Biosciences AG Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kuros Biosciences AG.

Kuros Biosciences AG Daily Stochastic Oscillator ChartKuros Biosciences AG Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kuros Biosciences AG.

Kuros Biosciences AG Daily Commodity Channel Index (CCI) ChartKuros Biosciences AG Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kuros Biosciences AG.

Kuros Biosciences AG Daily Chande Momentum Oscillator (CMO) ChartKuros Biosciences AG Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kuros Biosciences AG.

Kuros Biosciences AG Daily Williams %R ChartKuros Biosciences AG Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kuros Biosciences AG.

Kuros Biosciences AG Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kuros Biosciences AG.

Kuros Biosciences AG Daily Average True Range (ATR) ChartKuros Biosciences AG Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kuros Biosciences AG.

Kuros Biosciences AG Daily On-Balance Volume (OBV) ChartKuros Biosciences AG Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kuros Biosciences AG.

Kuros Biosciences AG Daily Money Flow Index (MFI) ChartKuros Biosciences AG Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kuros Biosciences AG.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-30ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-09STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Kuros Biosciences AG Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kuros Biosciences AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose35.551
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Kuros Biosciences AG with someone you think should read this too:
  • Are you bullish or bearish on Kuros Biosciences AG? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kuros Biosciences AG? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kuros Biosciences AG

I send you an email if I find something interesting about Kuros Biosciences AG.


Comments

How you think about this?

Leave a comment

Stay informed about Kuros Biosciences AG.

Receive notifications about Kuros Biosciences AG in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.